Home
|
|---|
On-line symposium: Atypical Use in Patients with Government Supported Benefits
|
Program Description / Statement of Need:
There is a high level of use of Antipsychotic medications (APMs) in Medicaid due to the high burden of mental illness. Atypical APMs such as aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone are used frequently and represent a significant cost to the Medicaid system. Are these APMs better, worse, or equal to older APMs?
Target Audience:
This activity has been designed to meet the educational needs of pharmacists, and other health care professionals working for state Medicaid programs who are interested in disease management programs for patients with diabetes, particularly in elderly patients, and those with serious mental illness.
Program Objectives:
After completing this activity, the participant should be better able to:
1. To consider Policies on Access to Atypicals: Evidence vs. Action on the Application of Medicaid Prior Authorization
2. Define Total Medical Care vs. Drug Costs for Treating Schizophrenia in the North Carolina Medicaid System
3. Describe the Association of Metabolic Risk with Atypical Use in a Managed Medicaid Population
Accreditation:
| ACPE Accreditation Statement | |
Educational Review Systems, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Through attending this program, up to 1.5 contact hours (0.15 CEU’s) may be awarded and a statement of credit issued to you upon completion of a program evaluation form, posttest (with a pass rate of 70% or higher) and an attendance verification form. The statement of credit will be issued immediately following the successful completion of these forms.
Credit Designation - CE
Educational Review Systems, Inc. designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (761-999-08-079-H04-P)
Sponsored by:
Accreditation for this program has expired.
Estimated time to complete activity: 1.5 hours
Cost of activity: No Charge.
Media: Web based learning activity
Faculty:
Diana Brixner, PhD, RPh (moderator)
Universitsity of Utah
Jennifer Polinski, MPH
Brigham and Women's Hospital
Harvard Medical School
Dale Christensen, PhD
University of North Carolina
Jeff Guo, PhD
Assistant Professor
University of Cincinnati
Viewing Requirements:
PC |
MAC |
On-line symposium: Atypical Use in Patients with Government Supported Benefits
Instructions:
Read the learning objectives and faculty disclosures above
Optionally, download and print the workbook so that you can take notes during the presentations
View the on-line program. You may view this is more that one session, and may pause or repeat any portion of the presentation if you need to.
Take the post-test
Accreditation for this program has expired. No CE certificates will be generated.
Download Polinski Presentation (.pdfs of Slides) - optional
Download Christensen Presentation (.pdfs of Slides) - optional
Download Guo Presentation (.pdfs of Slides) - optional
View the On-line Video / Powerpoint Presentations
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The JestaRx Group, Educational Resource Systesms, and the University of Utah do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent views of the JestaRx Group, Educational Resource Systesms, or the University of Utah . Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Support:
Supported through an educational grant from:
